MIT Technology Review names BenevolentAI as a top 10 breakthrough tech

Today we’re honoured to be named as one of MIT Technology Review’s top 10 breakthrough technologies of 2020.

The prestigious list, curated by MIT Technology Review’s editorial team, is subject to meticulous research and a rigorous process of elimination in order to identify the ten most important technology breakthroughs of the year which are expected to have the biggest impact on human life in the decade ahead.

AI-enabled molecules feature as one of the technologies on the 2020 list, where we’re proud to be recognised for our work in AI-driven chemical design. Our compound design is based on complex multiparametric optimisations set by medicinal chemists working alongside our AI scientists, with a scoring function that factors in all the properties we are seeking to optimise for that molecule.

David Rotman, Editor at Large, MIT Technology on the importance of AI-discovered molecules.:

"The ability of deep learning and other AI tools to find novel molecules with desirable properties will transform drug discovery. It promises to make the development of new medicines far faster and more effective, and is an important new tool in the hunt for better drugs."

Last year, we also released 'GuacaMol', an open-source Python framework that enables the entire research community to access generative chemistry models for benchmarking de novo molecular design.

Drug discovery scientists using our AI platform can select the most promising molecules. They can adapt and optimise compounds using interactive design tools and take them into synthesis and biological testing. Drug discovery scientists apply their knowledge (and bias) but, equally, they can become inspired by the AI and take their design in unexplored directions. Our aim is to empower scientists through the AI platform, believing that the best results come from feeding the interplay between scientists and AI.

The result is that drug discovery scientists can test a more accurate, smaller sample of compounds - cutting the time and cost of designing a drug by years. Our chemical design process is one component of a bigger integrated approach that spans from data collection, target identification up to clinical trials.Designing better medicines using AI and big data. Our team of scientists and AI experts present a ‘behind the scenes’ introduction to show how our latest advancements in machine learning and AI can better understand the underlying causes of diseases, and redefine the way in which new medicines are discovered and brought to patients.

More Posts

You Might Also Like

Intern at BenevolentAI part I: meet our 2020 intern cohort
What impactful work did our interns get up to across Engineering, Data Science, ML and business operations this summer? Get to know them and their work in our tech internships blog.
Nov 26, 2020
FDA grants Emergency Use Authorisation for baricitinib in hospitalised COVID-19 patients nine months after initial hypothesis was published by BenevolentAI
BenevolentAI scientists first identified baricitinib as a potential treatment for COVID-19 in early February 2020 using Benevolent's AI tools and biomedical knowledge graph.
Nov 20, 2020
NeurIPS 2020: Meet the BenevolentAI team
BenevolentAI is happy to announce it is sponsoring NeurIPS 2020. Join us to hear about data diversity and ML applied drug discovery, and to learn about careers in the field.
Nov 17, 2020
Careers with Impact: 5 learnings from machine learning applied drug discovery
Last week, we brought together four of our exceptional colleagues for a panel discussion on careers in machine learning applied drug discovery. Here are some of our main takeaways:
Nov 17, 2020
Data published in Science Advances shows baricitinib reduces COVID-19 morbidity and mortality
Research published in Science Advances supports BenevolentAI’s AI-generated hypothesis from late January for baricitinib as a treatment for COVID-19.
Nov 13, 2020
Sir Nigel Shadbolt joins BenevolentAI as a non-executive director
BenevolentAI strengthens its Board with the appointment of AI pioneer Sir Nigel Shadbolt as Non-Executive Director.
Nov 3, 2020